Picoplatin: Phase II started

NERX started an open-label, U.S. and Canadian Phase II trial in 75 patients to compare picoplatin with Hycamtin topotecan, a topoisomerase I inhibitor, as second-line therapy. GlaxoSmithKline plc (...